0001209191-21-023868.txt : 20210331 0001209191-21-023868.hdr.sgml : 20210331 20210331191139 ACCESSION NUMBER: 0001209191-21-023868 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210330 FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thompson Peter A. CENTRAL INDEX KEY: 0001357522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 21795312 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 FORMER NAME: FORMER CONFORMED NAME: Thompson Peter A DATE OF NAME CHANGE: 20060327 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-739-6451 MAIL ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-30 0 0001710072 Edgewise Therapeutics, Inc. EWTX 0001357522 Thompson Peter A. C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE. BOULDER CO 80303 1 0 1 0 Common Stock 2021-03-30 4 C 0 12730036 0.00 A 13046956 I See Footnotes Common Stock 2021-03-30 4 C 0 272724 0.00 A 272724 I See Footnotes Common Stock 2021-03-30 4 P 0 46875 16.00 A 319599 I See Footnotes Common Stock 2021-03-30 4 P 0 312500 16.00 A 13359456 I See Footnotes Series A Preferred Stock 0.00 2021-03-30 4 C 0 8187100 0.00 D Common Stock 8187100 0 I See Footnotes Series B-1 Preferred Stock 0.00 2021-03-30 4 C 0 1572960 0.00 D Common Stock 1572960 0 I See Footnotes Series B-2 Preferred Stock 0.00 2021-03-30 4 C 0 1301626 0.00 D Common Stock 1301626 0 I See Footnotes Series C Preferred Stock 0.00 2021-03-30 4 C 0 1668350 0.00 D Common Stock 1668350 0 I See Footnotes Series C Preferred Stock 0.00 2021-03-30 4 C 0 272724 0.00 D Common Stock 272724 0 I See Footnotes Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis. /s/ John R. Moore Attorney-in-Fact for Peter Thompson M.D. 2021-03-31